Tianda Pharmaceuticals Ltd. (HK:0455)
:0455
Want to see HK:0455 full AI Analyst Report?
Top Page
Tianda Pharmaceuticals Ltd.
(0455)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.09
▼(-31.54% Downside)
Action:Reiterated
Date:05/08/26
The score is primarily pressured by weak financial performance—persistent and worsening losses, margin compression, and declining revenue—despite manageable leverage and improved 2025 operating/free cash flow. Technicals further weigh on the outlook, with the stock below major moving averages and weak momentum signals. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Manageable leverage
Moderate debt-to-equity gives the company financial flexibility and lower interest burden versus highly leveraged peers. Over a 2–6 month horizon this reduces refinancing pressure, preserves capacity to fund operations or targeted investments, and limits default risk while profits remain under repair.
Negative Factors
Persistent losses and widening net margin
Sustained and worsening net losses materially erode retained earnings and constrain reinvestment. Over several months this limits capacity to scale commercial efforts or R&D, increases scrutiny from lenders and investors, and raises the probability management must pursue dilutive financing or cost cuts to survive.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
Moderate debt-to-equity gives the company financial flexibility and lower interest burden versus highly leveraged peers. Over a 2–6 month horizon this reduces refinancing pressure, preserves capacity to fund operations or targeted investments, and limits default risk while profits remain under repair.
Read all positive factors
Tianda Pharmaceuticals Ltd. (0455) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$195.65M
Dividend YieldN/A
Average Volume (3M)84.94K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth-2.12%
EPS Growth-13.99%
CountryHK
Employees701
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range i...
Tianda Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 322.94M | 329.94M | 532.09M | 546.69M | 509.96M |
| Gross Profit | 133.31M | 152.02M | 255.53M | 251.52M | 241.22M |
| EBITDA | -24.41M | -49.49M | 15.66M | -19.89M | -5.14M |
| Net Income | -70.00M | -61.37M | -24.16M | -54.64M | -21.67M |
Balance Sheet | |||||
| Total Assets | 747.83M | 765.02M | 917.29M | 1.09B | 1.16B |
| Cash, Cash Equivalents and Short-Term Investments | 64.81M | 85.69M | 162.44M | 343.44M | 334.00M |
| Total Debt | 132.66M | 127.44M | 113.60M | 141.05M | 160.43M |
| Total Liabilities | 291.46M | 259.36M | 325.35M | 434.23M | 375.08M |
| Stockholders Equity | 456.64M | 505.84M | 592.07M | 627.83M | 756.75M |
Cash Flow | |||||
| Free Cash Flow | 2.80M | -52.30M | -116.04M | 54.73M | -61.98M |
| Operating Cash Flow | 14.42M | -9.70M | -49.76M | 79.11M | -8.23M |
| Investing Cash Flow | -20.38M | -31.77M | -69.10M | -12.20M | 86.35M |
| Financing Cash Flow | -15.31M | -30.65M | -57.39M | -28.98M | -1.29M |
Tianda Pharmaceuticals Ltd. Technical Analysis
Negative
0.13
Price Trends
0.10
Negative
0.11
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
35.15
Neutral
35.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.10, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.15 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0455.
Tianda Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$823.45M | -45.08 | -3.39% | ― | -15.98% | 93.93% | |
52 Neutral | HK$192.97M | -5.88 | -6.17% | 3.51% | -6.69% | -266.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$167.53M | -39.14 | -11.77% | ― | 11.68% | -16.13% | |
46 Neutral | HK$356.60M | 43.65 | -1.17% | 7.50% | 59.60% | -351.02% | |
42 Neutral | HK$195.65M | -3.96 | -11.18% | ― | -2.12% | -13.99% | |
42 Neutral | HK$578.89M | -17.45 | 9.46% | ― | -36.32% | 78.17% |
* Healthcare Sector Average
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.05
-35.00%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.04
-11.11%
HK:1011
China NT Pharma Group Co., Ltd.
0.60
0.16
36.36%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.10
0.80
266.67%
HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
0.12
-0.04
-26.38%
HK:8622
Huakang Biomedical Holdings Company Limited
0.31
-0.09
-22.50%
Tianda Pharmaceuticals Ltd. Corporate Events
Tianda Pharmaceuticals Sets 2026 AGM and Seeks Share Buyback Mandate
Apr 29, 2026
Tianda Pharmaceuticals Limited has called its annual general meeting for 12 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and reports for the year ended 31 December 2025. The agenda also inclu...
Tianda Pharmaceuticals Sets Key Dates for 2026 AGM and Share Register Closure
Apr 29, 2026
Tianda Pharmaceuticals Limited has scheduled its 2026 annual general meeting for 12 June 2026 in Central, Hong Kong, setting 9 June 2026 as the record date for shareholders entitled to attend, speak and vote. To facilitate this, the company will c...
Tianda Pharmaceuticals Posts Wider 2025 Loss on Goodwill Impairment Despite Lower Expenses
Mar 26, 2026
Tianda Pharmaceuticals reported 2025 revenue of HK$322.9 million, slightly down from HK$329.9 million a year earlier, as the group maintained gross profit of HK$133.3 million but faced higher cost of sales. The company continues to operate across ...
Tianda Pharmaceuticals Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Tianda Pharmaceuticals Limited has scheduled a board meeting for 26 March 2026 to review and approve the audited final results for the financial year ended 31 December 2025. The board will also consider the declaration of a final dividend, a decis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.